Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Titan Pharma (TTNP)

Titan Pharma (TTNP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Titan Pharma 10 EAST 53RD STREET SUITE 3001 NEW YORK NY 10022 USA

www.titanpharm.com Employees: 4 P: 650-244-4990

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Titan Pharmaceuticals Inc was incorporated in Delaware in February 1992. The Company is a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Its product development programs engaged mainly in important pharmaceutical markets with significant unmet medical needs and commercial potential. The Company is directly developing its product candidates and also utilizes corporate, academic and government partnerships as appropriate. Such collaborations have helped to fund product development and have enabled the Company to retain significant economic interest in its products. Its main asset is Probuphine, the first slow release implant formulation of buprenorphine in development for the long term maintenance treatment of opioid dependence. It is designed to maintain a stable, around the clock blood level of the medicine in patients for six months following a single treatment. Probuphine is the first product to utilize ProNeura, its novel, proprietary, continuous drug delivery technology. Its ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions. It is currently evaluating drugs and disease settings for opportunities to develop this drug delivery technology for other potential treatment applications in situations where conventional treatment is limited by variability in blood drug levels and poor patient compliance. Fanapt (iloperidone) is another product, which is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis in the U.S. The manufacturing of Probuphine has mainly been conducted at DPT Laboratories, Inc. The Company competes with other pharmaceutical companies and specialized biotechnology companies. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.

Key Statistics

Overview:

Market Capitalization, $K 6,132
Enterprise Value, $K 3,302
Shares Outstanding, K 1,330
Float, K 1,321
% Float 99.28%
Short Interest, K 35
Days to Cover 1.64
Short Volume Ratio 0.10
% of Insider Shareholders 0.72%
% of Institutional Shareholders 31.49%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -4,710 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -690 K
EBIT, $ -2,610 K
EBITDA, $ -2,600 K

Growth:

1-Year Return -11.43%
3-Year Return -78.05%
5-Year Return -95.09%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 98.79%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.65 on 08/14/25
Next Earnings Date 01/02/26
Earnings Per Share ttm -2.95
EPS Growth vs. Prev Qtr -4.84%
EPS Growth vs. Prev Year 71.62%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payable Date 03/01/12
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 01/09/24

TTNP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -108.59%
Return-on-Assets % -95.64%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.20
Book Value/Share 2.10
Interest Coverage -0.03
60-Month Beta 1.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar